Novartis Gene Therapies.
Novartis Gene Therapies (formerly AveXis) is rethinking medicine to improve and extend the lives of people with rare genetic diseases such as spinal muscular atrophy. Since 2020, they have been leveraging the proficiency of comm:unications to disseminate information regarding their significant contributions in the medical domain. A significant amount of sensitivity and public relations expertise is necessary in this specific field of medicine to deliver information effectively while abiding by stringent compliance regulations. The activities of the pharmaceutical PR experts at comm:unications include strategic consulting, the media-friendly preparation of sensitive and complex content, the conceptualisation of press conferences and the preparation of media appearances, including media training.
The agency’s sustainable approach has set an example for other markets in Europe. comm:unications has been a ‘Preferred Partner’ for Novartis Austria since 2024. Take advantage of our expertise and contact us!
Sorry, no posts matched your criteria.